DXNVX Obtains International Certification for Information Security and Personal Data Management Systems

DXVX announced on the 21st that it has simultaneously obtained the international standards ISO/IEC 27001 for information security management systems and ISO/IEC 27701 for privacy information management systems.

The international standard certifications acquired by DXVX pertain to the management systems for information security and privacy protection in genomic analysis and clinical diagnostic services. Through this, the management system and a series of activities for information security and privacy protection have been officially recognized as meeting international standards, making it possible to objectively demonstrate the company's level of information security when launching services in the global market in the future.

DXVX plans to use this certification as an opportunity to further advance its information security management system and privacy information management system policies, physical security, and information access control systems. In particular, through standardized management that complies with global standards for information security and personally identifiable information, it plans to apply globally standardized information security and privacy information management systems in companion diagnostic (CDx) and various genomic analysis businesses.

In addition to genomic testing services requested by medical institutions, DXVX will also protect digitized genetic test results and manage the personal information of test requesters more securely in research service (CRO) collaborations with global clients.

A company representative stated, “With consumers’ awareness of information security and privacy protection increasing, by obtaining internationally recognized information security certifications, we will strengthen the protection of personal and consumer genetic information and secure differentiated service competitiveness.”

Meanwhile, DXVX recently launched an integrated companion diagnostic service and is receiving development requests from startups, bio venture companies, and pharmaceutical bio companies developing anticancer new drugs, and is preparing to launch services targeting overseas biopharmaceutical companies.

This content was produced with the assistance of AI translation services.